210 related articles for article (PubMed ID: 27195913)
1. Dasatinib promotes paclitaxel-induced necroptosis in lung adenocarcinoma with phosphorylated caspase-8 by c-Src.
Diao Y; Ma X; Min W; Lin S; Kang H; Dai Z; Wang X; Zhao Y
Cancer Lett; 2016 Aug; 379(1):12-23. PubMed ID: 27195913
[TBL] [Abstract][Full Text] [Related]
2. lncCRLA Enhanced Chemoresistance in Lung Adenocarcinoma That Underwent EpithelialMesenchymal Transition.
Min W; Sun L; Li B; Gao X; Zhang S; Zhao Y
Oncol Res; 2022 Jan; 28(9):857-872. PubMed ID: 33985619
[TBL] [Abstract][Full Text] [Related]
3. Fibronectin protects lung cancer cells against docetaxel-induced apoptosis by promoting Src and caspase-8 phosphorylation.
Qin S; Zhang B; Xiao G; Sun X; Li G; Huang G; Gao X; Li X; Wang H; Yang C; Ren H
Tumour Biol; 2016 Oct; 37(10):13509-13520. PubMed ID: 27465556
[TBL] [Abstract][Full Text] [Related]
4. Effects of VBMDMP on the reversal of cisplatin resistance in human lung cancer A549/DDP cells.
Wang CK; Zhang Y; Zhang ZJ; Qiu QW; Cao JG; He ZM
Oncol Rep; 2015 Jan; 33(1):372-82. PubMed ID: 25394854
[TBL] [Abstract][Full Text] [Related]
5. ABT-263, a Bcl-2 inhibitor, enhances the susceptibility of lung adenocarcinoma cells treated with Src inhibitors to anoikis.
Sakuma Y; Tsunezumi J; Nakamura Y; Yoshihara M; Matsukuma S; Koizume S; Miyagi Y
Oncol Rep; 2011 Mar; 25(3):661-7. PubMed ID: 21206976
[TBL] [Abstract][Full Text] [Related]
6. Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin.
Ceppi P; Papotti M; Monica V; Lo Iacono M; Saviozzi S; Pautasso M; Novello S; Mussino S; Bracco E; Volante M; Scagliotti GV
Mol Cancer Ther; 2009 Nov; 8(11):3066-74. PubMed ID: 19861409
[TBL] [Abstract][Full Text] [Related]
7. The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.
Le XF; Mao W; He G; Claret FX; Xia W; Ahmed AA; Hung MC; Siddik ZH; Bast RC
J Natl Cancer Inst; 2011 Sep; 103(18):1403-22. PubMed ID: 21813412
[TBL] [Abstract][Full Text] [Related]
8. The neurotoxicant PCB-95 by increasing the neuronal transcriptional repressor REST down-regulates caspase-8 and increases Ripk1, Ripk3 and MLKL expression determining necroptotic neuronal death.
Guida N; Laudati G; Serani A; Mascolo L; Molinaro P; Montuori P; Di Renzo G; Canzoniero LMT; Formisano L
Biochem Pharmacol; 2017 Oct; 142():229-241. PubMed ID: 28676433
[TBL] [Abstract][Full Text] [Related]
9. The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling.
Booth L; Roberts JL; Tavallai M; Webb T; Leon D; Chen J; McGuire WP; Poklepovic A; Dent P
Oncotarget; 2016 Apr; 7(15):19620-30. PubMed ID: 26934000
[TBL] [Abstract][Full Text] [Related]
10. SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells.
Langdon CG; Wiedemann N; Held MA; Mamillapalli R; Iyidogan P; Theodosakis N; Platt JT; Levy F; Vuagniaux G; Wang S; Bosenberg MW; Stern DF
Oncotarget; 2015 Nov; 6(35):37410-25. PubMed ID: 26485762
[TBL] [Abstract][Full Text] [Related]
11. LYN expression predicts the response to dasatinib in a subpopulation of lung adenocarcinoma patients.
Kim YJ; Hong S; Sung M; Park MJ; Jung K; Noh KW; Oh DY; Lee MS; Oh E; Shin YK; Choi YL
Oncotarget; 2016 Dec; 7(50):82876-82888. PubMed ID: 27756880
[TBL] [Abstract][Full Text] [Related]
12. Activation of Src mediates acquired cisplatin resistance in human lung carcinoma cells.
Jiang G; Liu Y; Wang R; Yu M; Zhang Y; Dong S; Liu H; Tong X
Anticancer Drugs; 2020 Feb; 31(2):123-130. PubMed ID: 31815763
[TBL] [Abstract][Full Text] [Related]
13. Cancer-associated fibroblasts treated with cisplatin facilitates chemoresistance of lung adenocarcinoma through IL-11/IL-11R/STAT3 signaling pathway.
Tao L; Huang G; Wang R; Pan Y; He Z; Chu X; Song H; Chen L
Sci Rep; 2016 Dec; 6():38408. PubMed ID: 27922075
[TBL] [Abstract][Full Text] [Related]
14. Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.
Ambrogio C; Gómez-López G; Falcone M; Vidal A; Nadal E; Crosetto N; Blasco RB; Fernández-Marcos PJ; Sánchez-Céspedes M; Ren X; Wang Z; Ding K; Hidalgo M; Serrano M; Villanueva A; Santamaría D; Barbacid M
Nat Med; 2016 Mar; 22(3):270-7. PubMed ID: 26855149
[TBL] [Abstract][Full Text] [Related]
15. Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells.
Shi M; Lou B; Ji J; Shi H; Zhou C; Yu Y; Liu B; Zhu Z; Zhang J
Cancer Chemother Pharmacol; 2013 Jul; 72(1):35-44. PubMed ID: 23712327
[TBL] [Abstract][Full Text] [Related]
16. Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.
Formisano L; D'Amato V; Servetto A; Brillante S; Raimondo L; Di Mauro C; Marciano R; Orsini RC; Cosconati S; Randazzo A; Parsons SJ; Montuori N; Veneziani BM; De Placido S; Rosa R; Bianco R
Oncotarget; 2015 Sep; 6(28):26090-103. PubMed ID: 26325669
[TBL] [Abstract][Full Text] [Related]
17. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD
Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-106a targets autophagy and enhances sensitivity of lung cancer cells to Src inhibitors.
Rothschild SI; Gautschi O; Batliner J; Gugger M; Fey MF; Tschan MP
Lung Cancer; 2017 May; 107():73-83. PubMed ID: 27372519
[TBL] [Abstract][Full Text] [Related]
19. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
[TBL] [Abstract][Full Text] [Related]
20. Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer.
Ceppi P; Rapa I; Lo Iacono M; Righi L; Giorcelli J; Pautasso M; Billè A; Ardissone F; Papotti M; Scagliotti GV
Int J Cancer; 2012 Apr; 130(8):1777-86. PubMed ID: 21618517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
